InMed 2026 Q1 Earnings EPS Narrows 83.8% Despite Increased Net Loss

InMed (INM) reported its fiscal 2026 Q1 earnings on Nov 7, 2025, with a revenue decline and narrowed losses. The results align with management’s focus on advancing Alzheimer’s candidate INM-901, though the company remains unprofitable.

Revenue

, , driven by pricing adjustments. Despite cost reductions in supply chain operations, the segment underperformed compared to the prior year.

Earnings/Net Income

, a 83.8% improvement, , reflecting persistent operational challenges. While EPS progress is positive, the overall financial outlook remains constrained by recurring losses.

Price Action

Shares fell 5.33% in the latest trading day, , , underscoring investor skepticism.

Post-Earnings Price Action Review

The strategy of buying INM shares after a revenue decline and holding for 30 days has historically underperformed, with an average return of -11.26% over three years. Consistently negative returns highlight market negativity toward the company’s financial performance.

CEO Commentary

, CEO, emphasized progress in INM-901’s preclinical development for Alzheimer’s, . He noted the addition of directors and Neil Klompas to strengthen governance and advance pipeline milestones.

Guidance

, contingent on BayMedica’s revenue and cost management. Key focus areas include GLP-enabling studies for INM-901 and IND submission preparation.

Additional News

Recent developments include the appointment of John Bathery and Neil Klompas to the board, both bringing pharmaceutical and biotech expertise to accelerate INM-901 and programs. , .

[Generated Title]

[Existing Article Opener]

[New 70-word Paragraph]

, . , . CEO Eric Adams highlighted progress in INM-901’s Alzheimer’s program and new board appointments to strengthen strategic execution. .

[Revenue]

[Earnings/Net Income]

[Price Action]

[Post Earnings Price Action Review]

[CEO Commentary]

[Guidance]

[Additional News]